Welcome to our dedicated page for Senti Biosciences Holdings SEC filings (Ticker: SNTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senti Biosciences SEC filings document a clinical-stage biotechnology issuer built around the Gene Circuit platform and its cell-therapy pipeline. The company’s 8-K reports cover operating and financial results, corporate updates, clinical or regulatory disclosures, shareholder voting matters, governance items, capital-structure matters and material agreements, including research-and-development laboratory lease disclosures.
The filing record also includes a Form 15-12G for Senti Biosciences, Inc. after a completed Delaware holding company reorganization under which Senti became a subsidiary within Senti Biosciences Holdings. That filing addresses termination or suspension of Exchange Act registration and reporting duties for the covered Senti common stock, alongside the issuer’s corporate-status and security-class disclosures.
Senti Biosciences Holdings, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add the Part III sections on directors, executive compensation, security ownership and related-party matters. The amendment does not change previously filed financial statements.
The filing details the board’s classified structure, committee memberships and independence determinations, as well as the non-employee director cash retainers and stock option program. It also summarizes 2025 pay for key executives, including salary, equity awards and potential severance on termination or change of control, and discloses equity plan capacity and major shareholders, with 31,144,754 common shares outstanding as of March 27, 2026.
Senti Biosciences Holdings, Inc. filed a Post-Effective Amendment No. 1 to its Form S-3 to reflect a holding company reorganization completed on April 24, 2026. The Successor Registrant expressly adopts the existing Registration Statement (No. 333-285985) under Rule 414. No additional securities are being registered by this Amendment. The filing describes the Merger Agreement effectuating the reorganization, confirms a one-for-one conversion of Predecessor common shares into Successor common shares, and incorporates the Successor’s amended certificate of incorporation and bylaws. The document also recites indemnification provisions, advancement of expenses, and indemnification agreements for officers and directors.
Senti Biosciences Holdings, Inc. filed a Post-Effective Amendment No. 1 to its Form S-3 on April 24, 2026 reflecting a holding company reorganization completed the same day. The amendment states that each outstanding share of the predecessor's common stock was converted into one share of the successor's common stock, and no additional securities are being registered by this amendment. The successor adopted organizational documents substantially identical to the predecessor's and expressly adopts the Registration Statement (File No. 333-285983) pursuant to Rule 414.
Senti Biosciences Holdings, Inc. filed Post-Effective Amendment No. 2 to its registration statement (Registration No. 333-265873) to reflect a holding company reorganization completed on April 24, 2026. The amendment states that 2,000,000 Earn-Out Shares originally registered are no longer issuable and have been removed from registration. The Successor Registrant adopted organizational documents substantially identical to the Predecessor and expressly adopts the prior registration statement under Rule 414. No additional securities are being registered pursuant to this amendment.
Senti Biosciences, Inc. files Post-Effective Amendment No. 2 to remove from registration the resale of 8,727,049 shares of its common stock previously registered for resale by Chardan Capital Markets LLC.
The amendment states the Registrant is no longer required to register the resale under the Registration Rights Agreement and has terminated the related offering.
Bayer HealthCare LLC and affiliated reporting persons filed an amended Schedule 13D showing a significant ownership position in Senti Biosciences, Inc. They report beneficial ownership of 6,142,848 shares of common stock, representing 17.82% of the company.
This total includes 3,333,000 shares underlying a warrant for Senti common stock that is exercisable in full within 60 days of the filing date. The ownership percentage is based on 31,144,497 Senti common shares outstanding as of March 19, 2026, as reported in the company’s Form 10-K.